Skip to main content

The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy.

Publication ,  Journal Article
Kerr, KM; Auger, WR; Marsh, JJ; Comito, RM; Fedullo, RL; Smits, GJ; Kapelanski, DP; Fedullo, PF; Channick, RN; Jamieson, SW; Moser, KM
Published in: Am J Respir Crit Care Med
July 2000

Pulmonary thromboendartectomy (PTE) for chronic thromboembolic pulmonary hypertension may be complicated by reperfusion lung injury. This has previously been demonstrated to be neutrophil-mediated. We postulated that blocking selectin-mediated adhesion of neutrophils to the endothelium with Cylexin (CY-1503) would prevent reperfusion lung injury in this patient population. In this double-blind, randomized, placebo-controlled, parallel study, 26 patients received Cylexin the day of surgery and 25 received placebo. Significantly fewer patients in the treated group (31%) compared with the placebo group (60%) developed lung injury (p = 0.036). However, the average number of days of mechanical ventilation, days in the intensive care unit (ICU) and hospital, as well as mortality were not significantly different between the treatment groups. Those with reperfusion lung injury had significantly elevated percent neutrophils, total protein, and soluble P-selectin in bronchoalveolar lavage fluid compared with those without lung injury. We conclude that reperfusion lung injury after PTE is a high-permeability lung injury and its incidence can be reduced by the administration of Cylexin on the day of surgery.

Duke Scholars

Published In

Am J Respir Crit Care Med

DOI

ISSN

1073-449X

Publication Date

July 2000

Volume

162

Issue

1

Start / End Page

14 / 20

Location

United States

Related Subject Headings

  • Respiratory System
  • Reperfusion Injury
  • Pulmonary Embolism
  • Oligosaccharides
  • Middle Aged
  • Male
  • Lewis Blood Group Antigens
  • Hypertension, Pulmonary
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kerr, K. M., Auger, W. R., Marsh, J. J., Comito, R. M., Fedullo, R. L., Smits, G. J., … Moser, K. M. (2000). The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am J Respir Crit Care Med, 162(1), 14–20. https://doi.org/10.1164/ajrccm.162.1.9712142
Kerr, K. M., W. R. Auger, J. J. Marsh, R. M. Comito, R. L. Fedullo, G. J. Smits, D. P. Kapelanski, et al. “The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy.Am J Respir Crit Care Med 162, no. 1 (July 2000): 14–20. https://doi.org/10.1164/ajrccm.162.1.9712142.
Kerr KM, Auger WR, Marsh JJ, Comito RM, Fedullo RL, Smits GJ, et al. The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am J Respir Crit Care Med. 2000 Jul;162(1):14–20.
Kerr, K. M., et al. “The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy.Am J Respir Crit Care Med, vol. 162, no. 1, July 2000, pp. 14–20. Pubmed, doi:10.1164/ajrccm.162.1.9712142.
Kerr KM, Auger WR, Marsh JJ, Comito RM, Fedullo RL, Smits GJ, Kapelanski DP, Fedullo PF, Channick RN, Jamieson SW, Moser KM. The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am J Respir Crit Care Med. 2000 Jul;162(1):14–20.

Published In

Am J Respir Crit Care Med

DOI

ISSN

1073-449X

Publication Date

July 2000

Volume

162

Issue

1

Start / End Page

14 / 20

Location

United States

Related Subject Headings

  • Respiratory System
  • Reperfusion Injury
  • Pulmonary Embolism
  • Oligosaccharides
  • Middle Aged
  • Male
  • Lewis Blood Group Antigens
  • Hypertension, Pulmonary
  • Humans
  • Female